InvestorsHub Logo
Followers 3
Posts 1981
Boards Moderated 1
Alias Born 11/02/2016

Re: None

Sunday, 04/18/2021 4:52:15 PM

Sunday, April 18, 2021 4:52:15 PM

Post# of 16445
Lets guess on schedule......






Here is maybe a clue on how many phases there will be and about what time schedule we are looking at.....so hope everyone is ready for the long haul because this is going take a while....who knows maybe I'm wrong and this dosn't match what we are looking at happening on RVA ?.....so I guess future patient studies are in Houston too ?

But who knows about estimates because this one says 2021 and I haven't seen anything lately on N-Assay and if it's still a go or on hold ?




"NanoLogix Update on Phase One PreTest Development

NanoLogix is pleased to provide an update on the development of a Screening/Pretest for use in conjunction with the N-Assay Rapid Bacteria Diagnostic.

The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).

This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.

This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.